Pancreatic cancer pill daraxonrasib shows survival boost in ASCO data
ASCO data show Revolution Medicines’ oral daraxonrasib, a molecular glue that blocks RAS, delaying cancer symptoms by more than nine months and extending median survival to 13.2 months in advanced pancreatic cancer; while not curative, it improves length and quality of life versus chemotherapy, with side effects like rash and mouth sores that are usually manageable.
